메뉴 건너뛰기




Volumn 76, Issue 2, 2012, Pages 177-182

Icotinib (BPI-2009H), a novel EGFR tyrosine kinase inhibitor, displays potent efficacy in preclinical studies

Author keywords

EGFR mutation; EGFR TKIs; Icotinib; In vivo; NSCLC

Indexed keywords

BPI 2009H; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; GEFITINIB; ICOTINIB; UNCLASSIFIED DRUG;

EID: 84859435053     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2011.10.023     Document Type: Article
Times cited : (133)

References (27)
  • 1
    • 0028955388 scopus 로고
    • Epidermal growth factor-related peptides and their receptors in human malignancies
    • Salomon D.S., Brandt R., Ciardiello F., Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 1995, 19:183-232.
    • (1995) Crit Rev Oncol Hematol , vol.19 , pp. 183-232
    • Salomon, D.S.1    Brandt, R.2    Ciardiello, F.3    Normanno, N.4
  • 2
    • 72049103970 scopus 로고    scopus 로고
    • Quantitative determination of icotinib in human plasma and urine using liquid chromatography coupled to tandem mass spectrometry
    • Liu D., Jiang J., Hu P., Tan F., Wang Y. Quantitative determination of icotinib in human plasma and urine using liquid chromatography coupled to tandem mass spectrometry. J Chromatogr B 2009, 877(30):3781-3786.
    • (2009) J Chromatogr B , vol.877 , Issue.30 , pp. 3781-3786
    • Liu, D.1    Jiang, J.2    Hu, P.3    Tan, F.4    Wang, Y.5
  • 3
    • 84873066370 scopus 로고    scopus 로고
    • Icotinib, a potent and selective oral EGFR inhibitor, is well tolerated and active in patients with NSCLC: results from a phase I/II trial
    • Zhao Q., Zhang L., Jiang J., Xu L., Shentu J., Liu D., et al. Icotinib, a potent and selective oral EGFR inhibitor, is well tolerated and active in patients with NSCLC: results from a phase I/II trial. 13th world conference on lung cancer (WCLC) 2009.
    • (2009) 13th world conference on lung cancer (WCLC)
    • Zhao, Q.1    Zhang, L.2    Jiang, J.3    Xu, L.4    Shentu, J.5    Liu, D.6
  • 4
    • 79960035905 scopus 로고    scopus 로고
    • Phase I study of icotinib hydrochloride (BPI-2009H), an oral EGFR tyrosine kinase inhibitor, in patients with advanced NSCLC and other solid tumors
    • AUGUST 2
    • Zhao Q., Shentu J., Xu N., Zhou J., Yang G., Yao Y., et al. Phase I study of icotinib hydrochloride (BPI-2009H), an oral EGFR tyrosine kinase inhibitor, in patients with advanced NSCLC and other solid tumors. Lung Cancer 2011, 73(August (2)):195-202.
    • (2011) Lung Cancer , vol.73 , pp. 195-202
    • Zhao, Q.1    Shentu, J.2    Xu, N.3    Zhou, J.4    Yang, G.5    Yao, Y.6
  • 5
    • 84859428976 scopus 로고    scopus 로고
    • A phase I/IIa study of icotinib hydrochloride, a novel oral EGFR-TKI, to evaluate its safety, tolerance, and preliminary efficacy in advanced NSCLC patients in China
    • Zhao Q., Zhou J., Shentu J., Xu N., Tan F. A phase I/IIa study of icotinib hydrochloride, a novel oral EGFR-TKI, to evaluate its safety, tolerance, and preliminary efficacy in advanced NSCLC patients in China. ASCO 2010 meeting report 2010.
    • (2010) ASCO 2010 meeting report
    • Zhao, Q.1    Zhou, J.2    Shentu, J.3    Xu, N.4    Tan, F.5
  • 6
    • 84873067615 scopus 로고    scopus 로고
    • ClinicalTrials.gov. Safety and efficacy study of Icotinb in non-small cell lung cancer (NSCLC) patients (ICOGEN). ClinicalTrials.gov identifier . Available at: [accessed January 16, 2011].
    • ClinicalTrials.gov. Safety and efficacy study of Icotinb in non-small cell lung cancer (NSCLC) patients (ICOGEN). ClinicalTrials.gov identifier . Available at: [accessed January 16, 2011]. http://clinicaltrials.gov/.
  • 7
    • 83455209248 scopus 로고    scopus 로고
    • A randomized, double-blind phase III study of icotinib versus gefitinib in patients with advanced non-small cell lung cancer (NSCLC) previously treated with chemotherapy (ICOGEN)
    • SUPPL. [abstr 7522]
    • Sun Y., Shi Y., Zhang L., Liu X., Zhou C., Zhang L., et al. A randomized, double-blind phase III study of icotinib versus gefitinib in patients with advanced non-small cell lung cancer (NSCLC) previously treated with chemotherapy (ICOGEN). J Clin Oncol 2011, 29(Suppl.). [abstr 7522].
    • (2011) J Clin Oncol , vol.29
    • Sun, Y.1    Shi, Y.2    Zhang, L.3    Liu, X.4    Zhou, C.5    Zhang, L.6
  • 8
    • 85040746919 scopus 로고    scopus 로고
    • A randomized, double-blind phase III study of Icotinib versus Gefitinib in patients with advanced non-small cell lung cancer (NSCLC) previously treated with chemotherapy(ICOGEN)
    • [abstr O10.06]
    • Sun Y., Shi Y., Zhang L., Liu X., Zhou C., Wang D., et al. A randomized, double-blind phase III study of Icotinib versus Gefitinib in patients with advanced non-small cell lung cancer (NSCLC) previously treated with chemotherapy(ICOGEN). 14th world conference on lung cancer (WCLC 2011, [abstr O10.06].
    • (2011) 14th world conference on lung cancer (WCLC
    • Sun, Y.1    Shi, Y.2    Zhang, L.3    Liu, X.4    Zhou, C.5    Wang, D.6
  • 9
    • 80052794272 scopus 로고    scopus 로고
    • Metabolite characterization of a novel anti-cancer agent, icotinib, in humans through liquid chromatography/quadrupole time-of-flight tandem mass spectrometry
    • Liu D., Jiang J., Zhang L., Tan F., Wang Y., Hu P. Metabolite characterization of a novel anti-cancer agent, icotinib, in humans through liquid chromatography/quadrupole time-of-flight tandem mass spectrometry. Rapid Commun Mass Spectrom 2011, 25(15):2131-2140.
    • (2011) Rapid Commun Mass Spectrom , vol.25 , Issue.15 , pp. 2131-2140
    • Liu, D.1    Jiang, J.2    Zhang, L.3    Tan, F.4    Wang, Y.5    Hu, P.6
  • 10
    • 79961057151 scopus 로고    scopus 로고
    • Tumor gene mutations and messenger RNA expression: correlation with clinical response to icotinib hydrochloride in non-small cell lung cancer
    • Ren G., Zhao Y., Zhu Y. Tumor gene mutations and messenger RNA expression: correlation with clinical response to icotinib hydrochloride in non-small cell lung cancer. Chin Med J 2011, 124(1):19-25.
    • (2011) Chin Med J , vol.124 , Issue.1 , pp. 19-25
    • Ren, G.1    Zhao, Y.2    Zhu, Y.3
  • 13
    • 0037229076 scopus 로고    scopus 로고
    • Targeting the epidermal growth factor receptor in cancer: apoptosis takes center stage
    • Kari C., Chan T.O., Quadros M.R., Rodeck U. Targeting the epidermal growth factor receptor in cancer: apoptosis takes center stage. Cancer Res 2003, 63:1-5.
    • (2003) Cancer Res , vol.63 , pp. 1-5
    • Kari, C.1    Chan, T.O.2    Quadros, M.R.3    Rodeck, U.4
  • 15
    • 0028142387 scopus 로고
    • A specific inhibitor of the epidermal growth factor receptor tyrosine kinase
    • Fry D.W., Kraker A.J., McMichael A., Ambroso L.A., Nelson J.M., Leopold W.R., et al. A specific inhibitor of the epidermal growth factor receptor tyrosine kinase. Science 1994, 265:1093-1095.
    • (1994) Science , vol.265 , pp. 1093-1095
    • Fry, D.W.1    Kraker, A.J.2    McMichael, A.3    Ambroso, L.A.4    Nelson, J.M.5    Leopold, W.R.6
  • 16
    • 9844235351 scopus 로고    scopus 로고
    • Use of a pharmacophore model for the design of EGF-R tyrosine kinase inhibitors: 4-(phenylamino)pyrazolo[3,4-d]pyrimidines
    • Traxler P., Bold G., Frei J., Lang M., Lydon N., Mett H., et al. Use of a pharmacophore model for the design of EGF-R tyrosine kinase inhibitors: 4-(phenylamino)pyrazolo[3,4-d]pyrimidines. J Med Chem 1997, 40:3601-3616.
    • (1997) J Med Chem , vol.40 , pp. 3601-3616
    • Traxler, P.1    Bold, G.2    Frei, J.3    Lang, M.4    Lydon, N.5    Mett, H.6
  • 18
    • 66949133946 scopus 로고    scopus 로고
    • Toxicity of anti-EGFR therapy in common cancers
    • Clinical Efficacy
    • Harandi A., Zaidi A.S., Stocker A.M., Laber D.A., Clinical Efficacy Toxicity of anti-EGFR therapy in common cancers. J Oncol 2009, 2009:567486.
    • (2009) J Oncol , vol.2009 , pp. 567486
    • Harandi, A.1    Zaidi, A.S.2    Stocker, A.M.3    Laber, D.A.4
  • 19
    • 77953930730 scopus 로고    scopus 로고
    • Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR
    • Maemondo M., Inoue A., Kobayashi K., Sugawara S., Qizumi S., Isobe H., et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010, 362:2380-2388.
    • (2010) N Engl J Med , vol.362 , pp. 2380-2388
    • Maemondo, M.1    Inoue, A.2    Kobayashi, K.3    Sugawara, S.4    Qizumi, S.5    Isobe, H.6
  • 20
    • 0012381722 scopus 로고    scopus 로고
    • Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (the IDEAL 1 trial)
    • Fukuoka M., Yano S., Giaccone G., Takagawa K., Douillard J.Y., Nishiwaki Y., et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (the IDEAL 1 trial). J Clin Oncol 2003, 21:2237-2246.
    • (2003) J Clin Oncol , vol.21 , pp. 2237-2246
    • Fukuoka, M.1    Yano, S.2    Giaccone, G.3    Takagawa, K.4    Douillard, J.Y.5    Nishiwaki, Y.6
  • 21
    • 4344646459 scopus 로고    scopus 로고
    • Determinants of tumor response and survival with erlotinib in patients with non-small cell lung cancer
    • Perez-Soler R., Chachoua A., Hammond L.A., Rowinsky E.K., Huberman M., Karp D., et al. Determinants of tumor response and survival with erlotinib in patients with non-small cell lung cancer. J Clin Oncol 2004, 22:3238-3247.
    • (2004) J Clin Oncol , vol.22 , pp. 3238-3247
    • Perez-Soler, R.1    Chachoua, A.2    Hammond, L.A.3    Rowinsky, E.K.4    Huberman, M.5    Karp, D.6
  • 22
    • 0142055937 scopus 로고    scopus 로고
    • Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with nonsmall cell lung cancer: a randomized trial
    • Kris M.G., Natale R.B., Herbst R.S., Lynch T.J., Prager D., Belani C.P., et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with nonsmall cell lung cancer: a randomized trial. JAMA 2003, 290:2149-2158.
    • (2003) JAMA , vol.290 , pp. 2149-2158
    • Kris, M.G.1    Natale, R.B.2    Herbst, R.S.3    Lynch, T.J.4    Prager, D.5    Belani, C.P.6
  • 23
    • 56249109644 scopus 로고    scopus 로고
    • Gefetinib versus docetaxel in previously treated non-small-cell lung caner (INTEREST): a randomised phase III trial
    • Kim E.S., Hirsh V., Mok T., Socinski M.A., Gervais R., Wu Y.L., et al. Gefetinib versus docetaxel in previously treated non-small-cell lung caner (INTEREST): a randomised phase III trial. Lancet 2008, 372:1809-1818.
    • (2008) Lancet , vol.372 , pp. 1809-1818
    • Kim, E.S.1    Hirsh, V.2    Mok, T.3    Socinski, M.A.4    Gervais, R.5    Wu, Y.L.6
  • 24
    • 84873064472 scopus 로고    scopus 로고
    • Phase III, randomized, open-label, first-line study of gefitinib(G) versus caboplatin/paclitaxel (C/P) in selected patients(pts) with advanced non-small-cell lung cancer(NSCLC) (IPASS): evaluation of recruits in Japan
    • Ohe Y., Ichinose Y., Nishiwaki Y., Yamamoto N., Negoro S., Duffield E., et al. Phase III, randomized, open-label, first-line study of gefitinib(G) versus caboplatin/paclitaxel (C/P) in selected patients(pts) with advanced non-small-cell lung cancer(NSCLC) (IPASS): evaluation of recruits in Japan. J Clin Oncol 2009, 27(Suppl.):8044.
    • (2009) J Clin Oncol , vol.27 , Issue.SUPPL. , pp. 8044
    • Ohe, Y.1    Ichinose, Y.2    Nishiwaki, Y.3    Yamamoto, N.4    Negoro, S.5    Duffield, E.6
  • 25
    • 27844589038 scopus 로고    scopus 로고
    • Identification of EGFR kinase domain mutations among lung cancer patients in China: implication for targeted cancer therapy
    • Qin B., Chen X., Zhu J., Pei D. Identification of EGFR kinase domain mutations among lung cancer patients in China: implication for targeted cancer therapy. Cell Res 2005, 15:212-217.
    • (2005) Cell Res , vol.15 , pp. 212-217
    • Qin, B.1    Chen, X.2    Zhu, J.3    Pei, D.4
  • 27
    • 3042634240 scopus 로고    scopus 로고
    • Tyrosine kinase inhibitors in cancer therapy
    • Madhusudan S., Ganesan T.S. Tyrosine kinase inhibitors in cancer therapy. Clin Biochem 2004, 37:618-635.
    • (2004) Clin Biochem , vol.37 , pp. 618-635
    • Madhusudan, S.1    Ganesan, T.S.2


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.